Results 71 to 80 of about 268,746 (338)

The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy

open access: yesFrontiers in Oncology, 2022
The emergence of checkpoint inhibitors has created a paradigm shift for the treatment of various malignancies. However, although these therapies are associated with improved survival rates, they also carry the risk of immune-related adverse events (irAEs)
Sebastian Bruera   +1 more
doaj   +1 more source

Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program [PDF]

open access: yes, 2019
Background: The Italian Renal Cell Cancer Early Access Program was an expanded access program that allowed access to nivolumab, for patients (pts) with metastatic renal cell carcinoma (mRCC) prior to regulatory approval.
Buti, S   +22 more
core   +3 more sources

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

open access: yesMolecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece   +18 more
wiley   +1 more source

Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies

open access: yesJournal for ImmunoTherapy of Cancer, 2020
In the last few years, the unprecedented results of immune checkpoint inhibitors have led to a paradigm shift in clinical practice for the treatment of several cancer types.
Alberto Puccini   +2 more
doaj   +1 more source

Immune Checkpoint Blockade Therapy May Be a Feasible Option for Primary Pulmonary Lymphoepithelioma-like Carcinoma

open access: yesFrontiers in Oncology, 2021
Primary pulmonary lymphoepithelioma-like carcinoma (PPLELC) is a rare subtype of non-small cell lung cancer (NSCLC) for which there is currently no recognized treatment.
Zuohong Wu   +5 more
doaj   +1 more source

Frontiers in Pigment Cell and Melanoma Research

open access: yes, 2018
We identify emerging frontiers in clinical and basic research of melanocyte biology and its associated biomedical disciplines. We describe challenges and opportunities in clinical and basic research of normal and diseased melanocytes that impact current ...
Birlea, Stanca   +26 more
core   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

open access: yesMolecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He   +8 more
wiley   +1 more source

Predictive Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Events [PDF]

open access: gold, 2023
Íñigo Les   +10 more
openalex   +1 more source

Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas [PDF]

open access: yes, 2018
This integrated, multiplatform PanCancer Atlas study co-mapped and identified distinguishing molecular features of squamous cell carcinomas (SCCs) from five sites associated with ...
Abdel-Rahman, Mohamed H.   +784 more
core   +2 more sources

Home - About - Disclaimer - Privacy